Thursday, 20 February 2014
AstraZeneca (NYSE:AZN) announced today that, in 2013, it provided nearly $975 million in savings to more than 567,000 patients in the United States through its patient assistance programs. These programs include AZ&Me and the MedImmune Assistance Program.
“At AstraZeneca, we work hard to understand the needs of patients, and we’re committed to helping them afford their medications,” said Paul Hudson, President, AstraZeneca U.S. and Executive Vice President, North America. “For more than 35 years, our patient assistance programs have been helping people access the medicines they need, and we look forward to bringing them continued savings and benefits in 2014.”
AstraZeneca’s AZ&Me prescription savings programs are designed to help qualifying people without insurance, those in Medicare Part D, those who receive their medications through participating health care facilities, and those who have faced a financial challenge recently.
- Individuals without Prescription Drug Coverage: AstraZeneca provides free medicines to qualifying individuals with an annual income at or below $35,000 and families of four with an annual household income at or below $70,000.
- Part D Beneficiaries: AstraZeneca provides free medicines to qualifying Medicare Part D beneficiaries with an annual income at or below $35,000 and couples with an annual household income at or below $48,000.
- Healthcare Facilities: AstraZeneca provides free medicines to qualifying non-profit organizations, such as disproportionate share hospitals, community health centers and community free clinics. This program helps provide medicines to qualifying patients at the time and place of treatment.
The MedImmune Assistance Program provides medication free of charge to qualified patients who are uninsured, or who have been rendered uninsured by their insurance company. Qualified patients must meet all eligibility criteria.
Click here for a visual overview of AstraZeneca’s prescriptions savings programs. For more detailed information about the AZ&Me prescription savings programs, please visitwww.astrazeneca-us.com or call 1-800-AZandMe (292-6363). For additional information about the MedImmune Assistance Program, visit www.myAccess360.com or call 1-877-778-9010.
AstraZeneca also participates in multi-manufacturer programs like the Partnership for Prescription Assistance and supports other organizations with the same goal—increasing access to medicines as well as health care.
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
For more information about AstraZeneca in the U.S. or our AZ&Me™ Prescription Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe (292-6363).
|Michele Meixell||302-885-2677, Michele.Meixell@AstraZeneca.com|
|Alisha Martin||302-885-2677, Alisha.Martin@AstraZeneca.com|